LOGIN  |  REGISTER
Astria Therapeutics
Cue Biopharma

Community Health Systems to Participate in the 2023 BofA Securities Leveraged Finance Conference

November 21, 2023 | Last Trade: US$2.97 0.13 -4.19

FRANKLIN, Tenn. / Nov 21, 2023 / Business Wire / Community Health Systems, Inc. (NYSE:CYH) today announced that management will participate in the 2023 BofA Securities Leveraged Finance Conference to be held November 27 – 29, 2023.

The investor presentation will begin at 8:50 a.m. Eastern time, 7:50 a.m. Central time, on Tuesday, November 28, 2023, and will be available to investors via a live audio webcast. A link to the broadcast can be found at the investor relations section of the Company’s website, www.chs.net, and a replay will be available using that same link.

About Community Health Systems, Inc.

Community Health Systems, Inc. is one of the nation’s largest healthcare companies. The Company's affiliates are leading providers of healthcare services, developing and operating healthcare delivery systems in 41 distinct markets across 15 states. CHS subsidiaries own or lease 74 affiliated hospitals with 12,000 beds and operate more than 1,000 sites of care, including physician practices, urgent care centers, freestanding emergency departments, occupational medicine clinics, imaging centers, cancer centers and ambulatory surgery centers. Shares in Community Health Systems, Inc. are traded on the New York Stock Exchange under the symbol “CYH.” The Company’s headquarters are located in Franklin, Tennessee, a suburb south of Nashville. More information about the Company can be found on its website at www.chs.net.

C4 Therapeutics

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page